1,2,3,4,6-pentagalloyl glucose



Compound IDCDAMM02048
Common name1,2,3,4,6-pentagalloyl glucose
IUPAC name[6-[2-oxo-2-(3,4,5-trihydroxyphenyl)ethyl]-3,4,5-tris[(3,4,5-trihydroxybenzoyl)oxy]oxan-2-yl]methyl 3,4,5-trihydroxybenzoate
Molecular formulaC42H34O25

Experimental data

Retention time17.77
Adduct[M+H]+
Actual mz939.145
Theoretical mz939.146
Error1.04
Ionizaton modePositive
Instrument typeLC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score6.4708

Identifiers and class information

Inchi keyQMQJHZMCRRSTQA-XGHHBHORSA-N
SmilesO=C(OCC1OC(CC(=O)C2=CC(O)=C(O)C(O)=C2)C(OC(=O)C3=CC(O)=C(O)C(O)=C3)C(OC(=O)C4=CC(O)=C(O)C(O)=C4)C1OC(=O)C5=CC(O)=C(O)C(O)=C5)C6=CC(O)=C(O)C(O)=C6
SuperclassOrganic acids and derivatives
ClassCarboxylic acids and derivatives

Pharmacokinetic properties

Number of descriptor values(#stars)16
Number of non-conjugated amine groups (#amine)0
Number of amidine and guanidine groups (#amidine)0
Number of carboxylic acid groups (#acid)0
Number of non-conjugated amide groups (#amide)0
Number of rotatable bonds (#rotor)27
Number of reactive functional groups (#rtvFG)4
Predicted central nervous system activity (CNS)-2
Molecular weight (mol_MW)938.716
Computed dipole moment(dipole)6.048
Total solvent accessible surface area (SASA)1139.75
Hydrophobic component of SASA (FOSA)60.509
Hydrophilic component of SASA (FISA)781.559
Pie component of the SASA (PISA)297.678
Weakly polar component of the SASA (WPSA)0
Total solvent accesible volume (volume)2314.46
Number of hydrogen bond donors (donorHB)15
Number of hydrogen bond acceptors (accptHB)22.95
Free energy of solvation of dipole (dip^2/V)0.0158064
Index of cohesive interaction in solids (ACxDN^.5/SA)0.0779866
Globularity descriptor (glob)0.742433
Predicted polarizability in cubic angstroms (QPpolrz)71.977
Predicted hexadecane/gas partition coefficient (QPlogPC16)30.861
Predicted octanol/gas partition coefficient (QPlogPoct)61.398
Predicted water/gas partition coefficient (QPlogPw)48.422
Predicted octanol/water partition coefficient (QPlogPo/w)-2.882
Predicted aqueous solubility (QPlogS)-3.175
Conformation-independent predicted aqueous solubility (CIQPlogS)-9.429
Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)-7.119
Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)0
Predicted brain/blood partition coefficient (QPlogBB)-10.517
Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)0
Predicted skin permeability, log Kp (QPlogKp)-12.283
PM3 calculated ionization potential (IP(ev))9.045
PM3 calculated electron affinity (EA(eV))0.738
Number of likely metabolic reactions (#metab)17
Prediction of binding to human serum albumin (QPlogKhsa)-1.338
Predicted qualitative human oral absorption (HumanOralAbsorption)1
Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)0
Solvent-accessible surface area of fluorine atoms (SAFluorine)0
Solvent-accessible surface area of amide oxygen atoms (SAamideO)0
Van der Waals surface area (PSA)487.741
Number of nitrogen and oxygen atoms (#NandO)25
Number of violations of Lipinski’s rule of five (RuleOfFive)3
Number of violations of Jorgensen’s rule of three (RuleOfThree)2

Compound-target network

Cytoscape Graph

Protein targets associated with phytocompound

Uniprot ID Gene name Target name TTD_ID Prediction source
O43570CA12Carbonic anhydrase XIIT16987SEA
Q16790CA9Carbonic anhydrase IXT64567SEA
P00915CA1Carbonic anhydrase IT13201SEA
P00918CA2Carbonic anhydrase IIT20401SEA
Q9ULX7CA14Carbonic anhydrase XIVT31992SEA
P06746POLBDNA polymerase beta (by homology)T06958SEA
P05121SERPINE1Plasminogen activator inhibitor-1T15556SEA
Q9NUW8TDP1Tyrosyl-DNA phosphodiesterase 1T33492SEA
P52209PGD6-phosphogluconate dehydrogenaseT76497SEA
P09382LGALS1Galectin-1T09544SEA
Q99417MYCBPMYCBP messenger RNAT37298SEA

Target associated diseases

TTD_ID Disease_ID Disease name ICD_11 Uniprot ID Gene names
T16987DI0046Bacterial infection[ICD-11: 1A00-1C4Z]O43570CA12
T16987DI0372Seborrhoeic dermatitis[ICD-11: EA81]O43570CA12
T64567DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]Q16790CA9
T13201DI0166Glaucoma[ICD-11: 9C61]P00915CA1
T13201DI0372Seborrhoeic dermatitis[ICD-11: EA81]P00915CA1
T20401DI0046Bacterial infection[ICD-11: 1A00-1C4Z]P00918CA2
T20401DI0137Essential hypertension[ICD-11: BA00]P00918CA2
T20401DI0166Glaucoma[ICD-11: 9C61]P00918CA2
T20401DI0175Heart failure[ICD-11: BD10-BD1Z]P00918CA2
T20401DI0214Insomnia[ICD-11: 7A00-7A0Z]P00918CA2
T20401DI0372Seborrhoeic dermatitis[ICD-11: EA81]P00918CA2
T31992DI0046Bacterial infection[ICD-11: 1A00-1C4Z]Q9ULX7CA14
T31992DI0204Inborn metabolism deficiency[ICD-11: 5C50-5C59]Q9ULX7CA14
T06958DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]P06746POLB
T15556DI0037Asthma[ICD-11: CA23]P05121SERPINE1
T15556DI0405Thrombosis[ICD-11: DB61-GB90]P05121SERPINE1
T76497DI0337Pituitary gland disorder[ICD-11: 5A60-5A61]P52209PGD
T37298DI0235Liver cancer[ICD-11: 2C12]Q99417MYCBP

Copyright © 2025